Literature DB >> 20377577

Joint modeling of the clinical progression and of the biomarkers' dynamics using a mechanistic model.

Jeremie Guedj1, Rodolphe Thiébaut, Daniel Commenges.   

Abstract

Joint models are used to rigorously explore the relationship between the dynamics of biomarkers and clinical events. In the context of HIV infection, where the multivariate dynamics of HIV-RNA and CD4 are complex, a mechanistic approach based on a system of nonlinear differential equations naturally takes into account the correlation between the biomarkers. Using data from a randomized clinical trial comparing dual antiretroviral therapy to a single drug regimen, a full maximum likelihood approach is proposed to explore the relationship between the evolution of the biomarkers and the time to a clinical event. The role of each marker as an independent predictor of disease progression is assessed. We show that the joint dynamics of HIV-RNA and CD4 captures the effect of antiretroviral treatment; the CD4 dynamics alone is found to capture most but not all of the treatment effect.
© 2010, The International Biometric Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20377577     DOI: 10.1111/j.1541-0420.2010.01418.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  4 in total

1.  Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Bernard Sébastien; Jérémie Guedj
Journal:  Biometrics       Date:  2016-05-05       Impact factor: 2.571

2.  Modelling of viral load dynamics and CD4 cell count progression in an antiretroviral naive cohort: using a joint linear mixed and multistate Markov model.

Authors:  Zelalem G Dessie; Temesgen Zewotir; Henry Mwambi; Delia North
Journal:  BMC Infect Dis       Date:  2020-03-26       Impact factor: 3.090

3.  Joint modelling of time-to-event and multivariate longitudinal outcomes: recent developments and issues.

Authors:  Graeme L Hickey; Pete Philipson; Andrea Jorgensen; Ruwanthi Kolamunnage-Dona
Journal:  BMC Med Res Methodol       Date:  2016-09-07       Impact factor: 4.615

4.  Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties.

Authors:  Daniel Scholes Rosenbloom; Ping Zhao; Vikram Sinha
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-08-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.